Toll Free (US):+1(800)9439753


Namzaric is a drug that is used to treat Alzheimer’s disease. It contains two active ingredients, memantine and donepezil. The dosage for Namzaric is 10 mg of memantine and 5 mg of donepezil. It can be taken orally once a day with or without food


Added to wishlistRemoved from wishlist 0
Add to compare
The orders are shipped to almost all countries of the worlds Including USA, Canada, United Kingdom and EU countries.
Express: 5-9 business days
Standard: 10-21 days
SKU: 88027 Category:

Namzaric is a newly approved drug by the FDA for the treatment of Alzheimer’s disease. It is a combination of memantine and donepezil, two drugs that have been used separately to treat Alzheimer’s. Namzaric has shown promising results in clinical trials in reducing symptoms of Alzheimer’s. The active ingredients are memantine and donepezil, which are both taken orally once a day. The dosage is either 5 mg/10 mg or 10 mg/20 mg, depending on how severe the patient’s symptoms are. Namzaric can be used alone or with other medications prescribed for Alzheimer’s patients. Some common side effects include nausea, vomiting, diarrhea, and loss of appetite. However, these side effects are usually mild and disappear over time. There have been some reports of increased confusion and agitation in patients taking Namzaric; however, this appears to be rare. Overall, Namzaric has been found to be safe and effective in treating symptoms of Alzheimer’s disease
Alzheimer’s Disease (AD) is one type dementia that progressively worsens over time leading to memory loss as well as impaired thinking skills (National Institute on Aging). Memantine hydrochloride plus donepezil hydrochloride controlled release capsules (Namzaric) was recently approved by the Food & Drug Administration as an adjunct treatment for moderate-to-severe AD (FDA News Release). This new medication contains 2 active ingredients: memantine hydrochloride which helps reduce glutamate levels; and donepezil hydrochloride which improves cholinergic function by blocking acetylcholinesterase enzyme activity thereby increasing acetylcholine levels at synaptic junctions between nerve cells involved in memory formation processes (ClinicalTrialsgov). In randomized double blind placebo controlled studies involving 1128 participants with moderate-to-severe AD who were treated with either 5mg/10mg or 10mg/20mg doses per day of NAMZARIC found significant improvement from baseline compared to those receiving placebo on measures including cognitive function tests such as Mini Mental State Examination score (-2 vs -1), Clinical Global Impression Severity Scale (-1 vs 0), Activities Of Daily Living Inventory total score (-5 vs -3), Behavior Rating Scale For Dementia score (-4 vs -2), Neuropsychiatric Inventory Questionnaire subscale scores sum total (-16 vs -11) indicating less neuropsychiatric problems being experienced by those treated with NAMZARIC

Specification: Namzaric


, , ,


User Reviews

0.0 out of 5
Write a review

There are no reviews yet.

Be the first to review “Namzaric”

Your email address will not be published.
Compare items
  • Total (0)
Shopping cart